Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Journal Volume
105
Date Issued
2021-02-13
Author(s)
Chen, Guan-Jhou
Su, Yi-Ching
Liu, Wen-Chun
Hung, Chien-Ching
Abstract
The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).
Subjects
Genetic barrier; Integrase strand transfer inhibitor; Nucleoside reverse transcriptase inhibitor; Resistance-associated mutation; Virological failure
SDGs
Other Subjects
abacavir; atazanavir; darunavir; dolutegravir; lamivudine; lopinavir; nonnucleoside reverse transcriptase inhibitor; proteinase inhibitor; RNA directed DNA polymerase inhibitor; tenofovir disoproxil; virus RNA; zidovudine; antiretrovirus agent; dolutegravir; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; proteinase inhibitor; pyridone derivative; adult; antiretroviral therapy; antiviral resistance; Article; CD4 lymphocyte count; cohort analysis; controlled study; drug substitution; drug withdrawal; female; follow up; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; human tissue; incidence; major clinical study; male; metabolic syndrome X; observational study; retrospective study; risk factor; treatment duration; unspecified side effect; viremia; virus load; clinical trial; Human immunodeficiency virus infection; middle aged; viremia; virology; virus load; Adult; Anti-Retroviral Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Incidence; Male; Middle Aged; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Viral Load; Viremia
Type
journal article